ASP Isotopes Inc. (ASPI) stock analysis
Basic Materials · Specialty Chemicals
From the 10-K filed 2026-04-10
How it makes money
It expects to sell enriched isotopes to a few large customers, though it currently has no sales from them.
The company aims to produce and commercialize enriched isotopes such as Carbon-14, Silicon-28, and Ytterbium-176 for industries including nuclear medicine, advanced semiconductors, and nuclear energy. Because it relies on specialized proprietary enrichment technologies, it expects to depend heavily on a small group of large customers for its future revenue generation.
At the same time, it has expanded through acquisitions to include construction activities via Skyline in Hong Kong and natural gas operations via Renergen in South Africa, broadening its underlying business mix beyond pure isotope enrichment.
What protects it: the moat
Management claims protection through proprietary enrichment technologies, though some key intellectual property lacks formal patent registration.
The company relies on its Aerodynamic Separation Process and Quantum Enrichment technology to build barriers against competitors in specialized material supply chains. However, management notes that certain intellectual property and proprietary rights held by the company and Renergen are not protected through patents or formal copyright registration.
What growth costs
It requires substantial additional capital to fund its ongoing operations, facility construction, and future development efforts.
The filing does not provide a specific numerical figure for ongoing capital expenditures, but explicitly states that the company will require substantial additional capital to finance its operations. It must continuously invest in constructing enrichment plants, advancing research and development for new isotopes, and pursuing acquisitions in the critical materials supply chain.
What could damage it
Regulatory barriers or denial of permissions for uranium enrichment could halt key growth initiatives and impair long-term earnings potential.
If the company fails to obtain necessary regulatory approvals or permissions to test and apply its enrichment technologies to Uranium-235, its planned nuclear fuel supply initiatives with partners like TerraPower would stall. This failure to secure regulatory clearance would undermine the anticipated commercial value of its uranium enrichment strategy.
About ASP Isotopes Inc.
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.